这是一篇来自已证抗体库的有关人类 MLANA的综述,是根据32篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合MLANA 抗体。
MLANA 同义词: MART-1; MART1; melanoma antigen recognized by T-cells 1; antigen LB39-AA; antigen SK29-AA; protein Melan-A

艾博抗(上海)贸易有限公司
小鼠 单克隆(M2-9E3)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 6a
艾博抗(上海)贸易有限公司 MLANA抗体(Abcam, ab187369)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (图 6a). Am J Hum Genet (2018) ncbi
兔 单克隆(EP1422Y)
  • 免疫细胞化学; 人类; 1:200; 图 6g
  • 免疫印迹; 人类; 1:200
艾博抗(上海)贸易有限公司 MLANA抗体(Abcam, EP1422Y)被用于被用于免疫细胞化学在人类样品上浓度为1:200 (图 6g) 和 被用于免疫印迹在人类样品上浓度为1:200. Nat Commun (2017) ncbi
兔 单克隆(EP1422Y)
  • 免疫组化; 人类; 图 s6b
艾博抗(上海)贸易有限公司 MLANA抗体(Abcam, EP1422Y)被用于被用于免疫组化在人类样品上 (图 s6b). Immunity (2017) ncbi
小鼠 单克隆(HMB45 + M2-7C10 + M2-9E3)
  • 流式细胞仪; 人类; 图 1
艾博抗(上海)贸易有限公司 MLANA抗体(Abcam, AB-ab732)被用于被用于流式细胞仪在人类样品上 (图 1). Oncotarget (2015) ncbi
兔 单克隆(EP1422Y)
  • 免疫组化-冰冻切片; 人类
艾博抗(上海)贸易有限公司 MLANA抗体(Abcam, ab51061)被用于被用于免疫组化-冰冻切片在人类样品上. PLoS ONE (2014) ncbi
小鼠 单克隆(DT101 + BC199)
  • 免疫组化-石蜡切片; 人类; 1:20
艾博抗(上海)贸易有限公司 MLANA抗体(Abcam, ab731)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:20. Cell Transplant (2014) ncbi
赛默飞世尔
小鼠 单克隆(M2-7C10)
  • 免疫细胞化学; 人类; 1:40; 图 4g
赛默飞世尔 MLANA抗体(Thermo fisher scientific, M2-7C10)被用于被用于免疫细胞化学在人类样品上浓度为1:40 (图 4g). Nat Commun (2017) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类; 1:100; 表 2
赛默飞世尔 MLANA抗体(NeoMarkers, A103/M2-72)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (表 2). Mod Pathol (2017) ncbi
小鼠 单克隆(A103)
  • 免疫组化; 人类; 1:100; 图 6
赛默飞世尔 MLANA抗体(Thermo, A103)被用于被用于免疫组化在人类样品上浓度为1:100 (图 6). Diagn Pathol (2015) ncbi
小鼠 单克隆(A103)
  • 免疫印迹; 小鼠
赛默飞世尔 MLANA抗体(Thermo Scientific, MS-799-P0)被用于被用于免疫印迹在小鼠样品上. Mol Oncol (2015) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 MLANA抗体(NeoMarkers, A103/M2-72)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Virchows Arch (2014) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MLANA抗体(Zymed laboratories, A103/M2-7C10/M2-9E3)被用于被用于免疫组化-石蜡切片在人类样品上. Am J Surg Pathol (2009) ncbi
小鼠 单克隆(M2-7C10)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 MLANA抗体(Zymed laboratories, A103/M2-7C10/M2-9E3)被用于被用于免疫组化-石蜡切片在人类样品上. Am J Surg Pathol (2009) ncbi
圣克鲁斯生物技术
小鼠 单克隆(A103)
  • 免疫印迹; 斑马鱼; 1:1000; 图 ex1a
圣克鲁斯生物技术 MLANA抗体(Santa, sc-20032)被用于被用于免疫印迹在斑马鱼样品上浓度为1:1000 (图 ex1a). Nature (2018) ncbi
小鼠 单克隆(D-1)
  • 免疫组化; 人类; 1:500; 图 3
圣克鲁斯生物技术 MLANA抗体(Santa Cruz Biotechnology, sc-271432)被用于被用于免疫组化在人类样品上浓度为1:500 (图 3). Oncol Lett (2016) ncbi
小鼠 单克隆(A103)
  • 免疫组化-冰冻切片; 小鼠
圣克鲁斯生物技术 MLANA抗体(Santa Cruz Biotechnology, sc-20032)被用于被用于免疫组化-冰冻切片在小鼠样品上. PLoS Genet (2014) ncbi
小鼠 单克隆(A103)
  • 免疫印迹; 小鼠; 图 2
圣克鲁斯生物技术 MLANA抗体(Santa Cruz Biotechnology, sc-20032)被用于被用于免疫印迹在小鼠样品上 (图 2). J Exp Med (2014) ncbi
BioLegend
小鼠 单克隆(M2-7C10)
  • 免疫组化-石蜡切片; 人类; 图 s1
BioLegend MLANA抗体(COVANCE, M2-7C10)被用于被用于免疫组化-石蜡切片在人类样品上 (图 s1). J Dermatol Sci (2017) ncbi
小鼠 单克隆(M2-7C10)
  • 免疫组化; 人类
BioLegend MLANA抗体(Covance, SIG-38160-1000)被用于被用于免疫组化在人类样品上. Clin Cancer Res (2013) ncbi
亚诺法生技股份有限公司
兔 单克隆(A19-P)
  • 免疫组化-冰冻切片; 人类; 图 3d
亚诺法生技股份有限公司 MLANA抗体(Abnova, MAB1656)被用于被用于免疫组化-冰冻切片在人类样品上 (图 3d). Sci Rep (2017) ncbi
丹科医疗器械技术服务(上海)有限公司
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 小鼠; 1:50; 图 st11
  • 免疫组化-石蜡切片; 狗; 1:50; 图 st11
  • 免疫组化-石蜡切片; 牛; 图 st11
  • 免疫组化-石蜡切片; 猫; 图 st11
  • 免疫组化-石蜡切片; 大鼠; 1:50; 图 st11
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(Dako, M7196)被用于被用于免疫组化-石蜡切片在小鼠样品上浓度为1:50 (图 st11), 被用于免疫组化-石蜡切片在狗样品上浓度为1:50 (图 st11), 被用于免疫组化-石蜡切片在牛样品上 (图 st11), 被用于免疫组化-石蜡切片在猫样品上 (图 st11) 和 被用于免疫组化-石蜡切片在大鼠样品上浓度为1:50 (图 st11). J Toxicol Pathol (2017) ncbi
小鼠 单克隆(A103)
  • 免疫组化; 人类; 1:100
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(DAKO, A103)被用于被用于免疫组化在人类样品上浓度为1:100. Diagn Pathol (2016) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类; 1:50
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(Dako, A103)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50. J Clin Invest (2016) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类; 图 1
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(Dako, M7196)被用于被用于免疫组化-石蜡切片在人类样品上 (图 1). Genome Biol (2016) ncbi
小鼠 单克隆(A103)
  • 流式细胞仪; 人类; 4800 ng/ml; 图 5
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(Dako, M7196)被用于被用于流式细胞仪在人类样品上浓度为4800 ng/ml (图 5). PLoS ONE (2016) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类; 图 1c
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(DakoCytomation, M719629)被用于被用于免疫组化-石蜡切片在人类样品上 (图 1c). Cell Rep (2016) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类; 图 2
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(Dako, M7196)被用于被用于免疫组化-石蜡切片在人类样品上 (图 2). Oncotarget (2016) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类; 1:50; 表 2
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(Dako, A103)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (表 2). Am J Surg Pathol (2016) ncbi
小鼠 单克隆(A103)
  • 免疫组化; 人类
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(Dako, M7196)被用于被用于免疫组化在人类样品上. J Invest Dermatol (2015) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类; 1:50
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(Dako, A103)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50. Nat Genet (2014) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类; 1:100
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(Dako, M7196)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Br J Dermatol (2014) ncbi
小鼠 单克隆(A103)
  • 免疫组化; 狗; 1:50
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(Dako A/S, A103)被用于被用于免疫组化在狗样品上浓度为1:50. J Comp Pathol (2014) ncbi
小鼠 单克隆(A103)
  • 免疫组化; 人类; 1:100; 表 3
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(DAKO, M7196)被用于被用于免疫组化在人类样品上浓度为1:100 (表 3). Am J Pathol (2011) ncbi
小鼠 单克隆(A103)
  • 免疫组化-石蜡切片; 人类
丹科医疗器械技术服务(上海)有限公司 MLANA抗体(DAKO, A103)被用于被用于免疫组化-石蜡切片在人类样品上. Melanoma Res (2010) ncbi
文章列表
  1. Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, de Tullio P, et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature. 2018;558:605-609 pubmed 出版商
  2. Yang C, Lin S, Chiang C, Wu Y, H ng W, Chang C, et al. Loss of GPNMB Causes Autosomal-Recessive Amyloidosis Cutis Dyschromica in Humans. Am J Hum Genet. 2018;102:219-232 pubmed 出版商
  3. Patwardhan A, Bardin S, Miserey Lenkei S, Larue L, Goud B, Raposo G, et al. Routing of the RAB6 secretory pathway towards the lysosome related organelle of melanocytes. Nat Commun. 2017;8:15835 pubmed 出版商
  4. Miyashita H, Niwano H, Yoshida S, Hatou S, Inagaki E, Tsubota K, et al. Long-term homeostasis and wound healing in an in vitro epithelial stem cell niche model. Sci Rep. 2017;7:43557 pubmed 出版商
  5. Cheuk S, Schlums H, Gallais Sérézal I, Martini E, Chiang S, Marquardt N, et al. CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin. Immunity. 2017;46:287-300 pubmed 出版商
  6. Furukawa S, Nagaike M, Ozaki K. Databases for technical aspects of immunohistochemistry. J Toxicol Pathol. 2017;30:79-107 pubmed 出版商
  7. Xia Q, Wang Z, Chen N, Gan H, Teng X, Shi S, et al. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement. Mod Pathol. 2017;30:416-426 pubmed 出版商
  8. Kaji T, Yamasaki O, Takata M, Otsuka M, Hamada T, Morizane S, et al. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity. J Dermatol Sci. 2017;85:51-57 pubmed 出版商
  9. Yu L, Li J, Xu S, Navia Miranda M, Wang G, Duan Y. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report. Diagn Pathol. 2016;11:98 pubmed
  10. Lund A, Wagner M, Fankhauser M, Steinskog E, Broggi M, Spranger S, et al. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016;126:3389-402 pubmed 出版商
  11. Nelson D, Jaber Hijazi F, Cole J, Robertson N, Pawlikowski J, Norris K, et al. Mapping H4K20me3 onto the chromatin landscape of senescent cells indicates a function in control of cell senescence and tumor suppression through preservation of genetic and epigenetic stability. Genome Biol. 2016;17:158 pubmed 出版商
  12. Talar B, Gajos Michniewicz A, Talar M, Chouaib S, Czyz M. Pentoxifylline Inhibits WNT Signalling in ?-Cateninhigh Patient-Derived Melanoma Cell Populations. PLoS ONE. 2016;11:e0158275 pubmed 出版商
  13. Kemper K, Krijgsman O, Kong X, Cornelissen Steijger P, Shahrabi A, Weeber F, et al. BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Rep. 2016;16:263-277 pubmed 出版商
  14. Liu W, Meng Z, Liu H, Li W, Wu Q, Zhang X, et al. Hepatic epithelioid angiomyolipoma is a rare and potentially severe but treatable tumor: A report of three cases and review of the literature. Oncol Lett. 2016;11:3669-3675 pubmed
  15. Hahn S, Neuhoff A, Landsberg J, Schupp J, Eberts D, Leukel P, et al. A key role of GARP in the immune suppressive tumor microenvironment. Oncotarget. 2016;7:42996-43009 pubmed 出版商
  16. Ertoy Baydar D, Kosemehmetoglu K, Aydin O, Bridge J, Buyukeren B, Aki F. Primary sclerosing epithelioid fibrosarcoma of kidney with variant histomorphologic features: report of 2 cases and review of the literature. Diagn Pathol. 2015;10:186 pubmed 出版商
  17. Agaimy A, Specht K, Stoehr R, Lorey T, Märkl B, Niedobitek G, et al. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker. Am J Surg Pathol. 2016;40:181-91 pubmed 出版商
  18. Galore Haskel G, Nemlich Y, Greenberg E, Ashkenazi S, Hakim M, Itzhaki O, et al. A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. Oncotarget. 2015;6:28999-9015 pubmed 出版商
  19. Woan K, Lienlaf M, Perez Villaroel P, Lee C, Cheng F, Knox T, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015;9:1447-1457 pubmed 出版商
  20. Wagner R, Luciani F, Cario André M, Rubod A, Petit V, Benzekri L, et al. Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo. J Invest Dermatol. 2015;135:1810-1819 pubmed 出版商
  21. DiTommaso T, Cottle D, Pearson H, Schlüter H, Kaur P, Humbert P, et al. Keratin 76 is required for tight junction function and maintenance of the skin barrier. PLoS Genet. 2014;10:e1004706 pubmed 出版商
  22. Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J Exp Med. 2014;211:2249-63 pubmed 出版商
  23. Shen Q, Rao Q, Xia Q, Yu B, Shi Q, Zhang R, et al. Perivascular epithelioid cell tumor (PEComa) with TFE3 gene rearrangement: clinicopathological, immunohistochemical, and molecular features. Virchows Arch. 2014;465:607-13 pubmed 出版商
  24. Wang X, Bledsoe K, Graham R, Asmann Y, Viswanatha D, Lewis J, et al. Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma. Nat Genet. 2014;46:666-8 pubmed 出版商
  25. Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B, et al. Inflammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol. 2014;170:816-23 pubmed 出版商
  26. Dziasko M, Armer H, Levis H, Shortt A, Tuft S, Daniels J. Localisation of epithelial cells capable of holoclone formation in vitro and direct interaction with stromal cells in the native human limbal crypt. PLoS ONE. 2014;9:e94283 pubmed 出版商
  27. Locher H, Frijns J, Huisman M, Chuva de Sousa Lopes S. TUBB3: neuronal marker or melanocyte mimic?. Cell Transplant. 2014;23:1471-3 pubmed 出版商
  28. Yasuno K, Nishiyama S, Kobayashi R, Yoshimura H, Takahashi K, Omachi T, et al. Proliferative lesions of intra-epidermal cytokeratin CAM5.2-positive cells in canine nipples. J Comp Pathol. 2014;150:18-26 pubmed 出版商
  29. Frederick D, Piris A, Cogdill A, Cooper Z, Lezcano C, Ferrone C, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19:1225-31 pubmed 出版商
  30. Chui J, Coroneo M, Tat L, Crouch R, Wakefield D, Di Girolamo N. Ophthalmic pterygium: a stem cell disorder with premalignant features. Am J Pathol. 2011;178:817-27 pubmed 出版商
  31. Helmke B, Zahel T, Breinig M, Schirmacher P, Aulmann S, Kern M. Her2 overexpression is a rare event in anorectal melanoma. Melanoma Res. 2010;20:431-4 pubmed 出版商
  32. Ryan P, Nguyen V, Gholoum S, Carpineta L, Abish S, Ahmed N, et al. Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract. Am J Surg Pathol. 2009;33:475-82 pubmed 出版商